Compare

DocMorris AG/Fr. DOCM

1D1W1M3M6MYTD1Y5YMAX

About DocMorris AG

DocMorris AG is a company operating in the pharmaceutical and healthcare sector, specializing in the distribution of medications and health-related products primarily through digital channels. The company is headquartered in Switzerland and focuses on providing an online platform for customers to purchase prescription and over-the-counter medicines, as well as other health products. DocMorris AG leverages digital technology to offer convenient access to healthcare products, catering to a broad European market. The company's strategic use of e-commerce in the pharmacy sector positions it uniquely to meet the growing demand for online health services.
Ticker
Fr. DOCM
Sector
Consumer Essentials
Primary listing
XSWX
Employees
1,337
Headquarters
Frauenfeld, Switzerland
Website
corporate.docmorris.com/en

DocMorris AG Metrics

BasicAdvanced
CHF 812M
-
-CHF 2.61
1.86
-

What the Analysts think about DocMorris AG

Analyst ratings (Buy, Hold, Sell) for DocMorris AG stock.
Analyst projections of the future price of DocMorris AG stock.

Bulls say / Bears say

German prescription sales grew 38.3% in the first half, accelerating to 45.8% in the second quarter, and DocMorris raised its full-year Rx growth forecast to about 40%. More repeat orders and new customers suggest the momentum is translating into a larger customer base. (DocMorris AG)
Digital Services revenue grew 71.4% in the first half and the segment doubled its EBITDA, giving DocMorris a fast-growing business beyond medicine sales. Management expects this segment to grow by more than 50% for 2026. (DocMorris AG)
Adjusted EBITDA improved to a CHF 10.9 million loss in the first half, from a CHF 28.8 million loss a year earlier. A planned AI-led efficiency programme is expected to deliver at least CHF 15 million in annual savings, supporting the path towards profitability. (DocMorris AG, DocMorris AG)
DocMorris remained loss-making, with a CHF 53.1 million net loss in the first half, while cash and short-term financial assets fell to CHF 99.2 million from CHF 159.5 million at year-end. That leaves limited room for error if cash burn stays high. (DocMorris AG)
A Hamburg court ordered DocMorris to stop a prescription voucher campaign, finding it unlawful; the ruling was not yet final. If similar promotions are restricted, the company could lose a tool for winning prescription customers. (Pharmazeutische Zeitung)
Growth is heavily reliant on German prescription sales: these rose 38.3% in the first half, while non-prescription revenue grew 6.6% and European revenue just 3.9% in local currency. That leaves less support if German Rx growth slows. (DocMorris AG)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2026.

DocMorris AG Financial Performance

Revenues and expenses
Income statement
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
Net income
Profit margin

DocMorris AG Earnings Performance

Company profitability
Earnings per share
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
Expected
Surprise

Funds containing DocMorris AG

Funds
Fund name
Fund size
Fr. DOCM weighting
iShares Digitalisation£DGIT
$813M0.03%
iShares Digitalisation$DGTL
$761M0.03%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.